Atlanta Business Chronicle by Urvaksh Karkaria, Staff Writer
A biotech startup backed by the former CEO of Serologicals Corp. and Solvay Pharmaceuticals Inc. is considering Atlanta as the site of its headquarters — a move that could create up to 250 jobs.
VaxyGen Vaccines Ltd. has the exclusive rights to commercialize the Serum Institute of India’s (SII) vaccine products in North America and the European Union. The Serum Institute is the world’s fifth-largest vaccine manufacturer and the world’s largest producer of measles and DTP (diphtheria, tetanus and pertussis) group of vaccines.
Under the agreement, SII does vaccine development and manufacturing and VaxyGen is responsible for clinical trials, regulatory
